Liu Simeng, Luo Renfei, Li Davey, Tang Anna, Qiu Yuli, Sherrier Ryan P, Aube Jeffrey, Wu Xiaoqing, Xu Liang, Huang Yufeng
Division of Nephrology & Hypertension, Department of Internal Medicine, University of Utah Health Science, Salt Lake City, UT, USA.
Division of Nephrology, Department of Internal Medicine, Nanjing Medical University Jiangsu Province Hospital, Nanjing, China.
Clin Sci (Lond). 2025 Jan 15;139(1):69-84. doi: 10.1042/CS20241756.
Septic acute kidney injury (AKI) is an important risk factor for developing chronic kidney disease (CKD). Hu antigen R (HuR) is recognized as a crucial modulator in inflammation. We hypothesized that elevated HuR contributes to the transition from septic AKI to CKD by promoting persistent inflammation and fibrosis, and inhibition of HuR may reverse septic kidney injury. Mice subjected to lipopolysaccharide (LPS) injections every other day were concurrently treated without or with either KH39 or niclosamide (NCS) for 7 days. Control mice received saline injections. Repeated LPS injections led to a significant increase in HuR expression in the kidneys, which was effectively suppressed by KH39 or NCS treatment. LPS-induced kidney injury was characterized by elevated plasma blood urea nitrogen levels and urinary albuminuria, along with histological signs of inflammatory cell infiltration and fibrosis, as determined by periodic acid-Schiff and Masson's trichrome staining, and immunofluorescent staining for markers such as α-smooth muscle actin, fibronectin, collagen III, and F4/80. Treatment with either KH39 or NCS mitigated these changes observed in LPS-injured kidneys. Additionally, increased expression of CD147, a molecule implicated in inflammatory cell recruitment and tubular injury, was inhibited by KH39 or NCS treatment. These effects on HuR and CD147 expression were further validated in vitro in cultured macrophages and tubular cells. This study suggests that HuR elevation in LPS-stimulated macrophages and kidney cells contributes to the progression of septic kidney injury, possibly through HuR-CD147 interactions, underscoring the therapeutic potential of HuR inhibitors for this condition.
脓毒症急性肾损伤(AKI)是发展为慢性肾脏病(CKD)的一个重要危险因素。Hu抗原R(HuR)被认为是炎症中的关键调节因子。我们假设HuR升高通过促进持续性炎症和纤维化导致从脓毒症AKI向CKD的转变,抑制HuR可能逆转脓毒症肾损伤。每隔一天接受脂多糖(LPS)注射的小鼠同时接受无KH39或尼可刹米(NCS)的治疗,持续7天。对照小鼠接受生理盐水注射。重复LPS注射导致肾脏中HuR表达显著增加,而KH39或NCS治疗可有效抑制这种增加。LPS诱导的肾损伤表现为血浆血尿素氮水平升高和尿白蛋白尿,以及炎症细胞浸润和纤维化的组织学迹象,这通过过碘酸希夫染色和Masson三色染色以及α-平滑肌肌动蛋白、纤连蛋白、III型胶原蛋白和F4/80等标志物的免疫荧光染色来确定。用KH39或NCS治疗减轻了在LPS损伤肾脏中观察到的这些变化。此外,参与炎症细胞募集和肾小管损伤的分子CD147的表达增加被KH39或NCS治疗所抑制。在体外培养的巨噬细胞和肾小管细胞中进一步验证了对HuR和CD147表达的这些影响。这项研究表明,LPS刺激的巨噬细胞和肾细胞中HuR升高可能通过HuR - CD147相互作用导致脓毒症肾损伤的进展,强调了HuR抑制剂对这种疾病的治疗潜力。